Kristine M. Ball
Director · Oruka Therapeutics, Inc.
Individual
- 2025
- Jun 3, 2026
- 2
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kristine M. Ball files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Fairmount Funds Management LLC - $300.01M in ORKA purchases and sales in the last 12 months
- Lawrence Otto Klein - $9.40M in ORKA purchases and sales in the last 12 months
- Carl Dambkowski - $8.65M in ORKA purchases and sales in the last 12 months
- Paul T. Quinlan - $6.76M in ORKA purchases and sales in the last 12 months
- Arjun Agarwal - $5.14M in ORKA purchases and sales in the last 12 months
- Joana Goncalves - $4.54M in ORKA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kristine M. Ball?
Kristine M. Ball is a corporate insider, tracked as Director of Oruka Therapeutics, Inc. (ORKA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Kristine M. Ball last file a Form 4?
The most recent primary Form 4 on record is dated 3 June 2026, one of 2 filings going back to 2025.